An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: Potential application for preclinical studies

Ramzi M. Mohammad, Ayad Al-Katib, George Pettit, Vainutis K. Vaitkevicius, Urwashi Joshi, Volkan Adsay, Adhip P N Majumdar, Fazlul H. Sarkar

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma is one of the most incurable and least understood of all human cancers. It is the fourth leading cause of cancer- related mortality in males (after lung, prostate, and colon) and in females (after lung, breast, and colon) in the United States with <2-3% of patients surviving >5 years. In an attempt to search for more effective therapies for this disease, we report here, for the first time, an effective treatment, the combination of gemcitabine and auristatin-phenethylamine (PE), against an orthotopic implantation of a human pancreatic adenocarcinoma cell line (HPAC) in severe combined immunodeficient (SCID) mice. Tumor implantation was performed by injecting 100 μl of the HPAC cell suspension (1 x 106 cells) directly into the pancreas of 5-week-old SCID mice. After implantation, tumor formation was checked twice a week. All palpable tumors were detected within 21 days (100% take rate), and tumors were confirmed histologically to be pancreatic adenocarcinoma. For the subsequent efficacy trial, tumor-bearing SCID mice were randomized into four groups with five mice in each group. One served as a control, the second received gemcitabine alone (2.5 mg/kg/injection i.p.), the third received auristatin-PE alone (2.0 mg/kg/injection i.v.), and the fourth group received the combination of gemcitabine (i.p.) and auristatin-PE (1.5 mg/kg/injection i.v.). All animals were euthanized 7 days after the completion of their treatments, and the pancreases were resected. Histological examination revealed the tumors to be adenocarcinoma. The tumors were composed of diffuse sheets of cells interrupted by glandular spaces containing secretory material. Cytologically, the tumor cells were large, pleomorphic, and hyperchromatic. Many cells contained intracellular lumina containing mucin. Immunohistochemical studies showed strong p21(WAFI) (p21) expression but no immunoreactivity with p53 and Her-2/neu antibodies. The mean pancreatic weight in the gemcitabine/auristatin-PE combination group was significantly (P = 0.014) lower (0.84 ± 0.639 g) when compared with those of the control (2.91 ± 1.19 g) and gemcitabine alone (1.84 ± 0.796 g; P = 0.064) groups. In addition, the mean weight in the combination group approached statistical significance when compared with the auristatin-PE group alone (1.16 ± 0.635 g; P = 0.028). We conclude that the combination of gemcitabine and auristatin-PE is an effective treatment against HPAC tumors in this xenograft model and more effective than treatment with either gemcitabine or auristatin-PE alone and could be considered for future animal studies with pancreas cancer and/or for human clinical trials.

Original languageEnglish (US)
Pages (from-to)887-894
Number of pages8
JournalClinical Cancer Research
Volume4
Issue number4
StatePublished - Apr 1998

Fingerprint

gemcitabine
SCID Mice
Pancreatic Neoplasms
Adenocarcinoma
Neoplasms
Injections
Pancreas
Colon
Therapeutics
Weights and Measures
Cell Line
Lung
Mucins
auristatin
phenethylamine
Tumor Cell Line
Heterografts
Prostate
Suspensions
Breast

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mohammad, R. M., Al-Katib, A., Pettit, G., Vaitkevicius, V. K., Joshi, U., Adsay, V., ... Sarkar, F. H. (1998). An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: Potential application for preclinical studies. Clinical Cancer Research, 4(4), 887-894.

An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice : Potential application for preclinical studies. / Mohammad, Ramzi M.; Al-Katib, Ayad; Pettit, George; Vaitkevicius, Vainutis K.; Joshi, Urwashi; Adsay, Volkan; Majumdar, Adhip P N; Sarkar, Fazlul H.

In: Clinical Cancer Research, Vol. 4, No. 4, 04.1998, p. 887-894.

Research output: Contribution to journalArticle

Mohammad, RM, Al-Katib, A, Pettit, G, Vaitkevicius, VK, Joshi, U, Adsay, V, Majumdar, APN & Sarkar, FH 1998, 'An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: Potential application for preclinical studies', Clinical Cancer Research, vol. 4, no. 4, pp. 887-894.
Mohammad, Ramzi M. ; Al-Katib, Ayad ; Pettit, George ; Vaitkevicius, Vainutis K. ; Joshi, Urwashi ; Adsay, Volkan ; Majumdar, Adhip P N ; Sarkar, Fazlul H. / An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice : Potential application for preclinical studies. In: Clinical Cancer Research. 1998 ; Vol. 4, No. 4. pp. 887-894.
@article{ab007c842cfc43ea88cde6b4994d7a67,
title = "An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: Potential application for preclinical studies",
abstract = "Pancreatic adenocarcinoma is one of the most incurable and least understood of all human cancers. It is the fourth leading cause of cancer- related mortality in males (after lung, prostate, and colon) and in females (after lung, breast, and colon) in the United States with <2-3{\%} of patients surviving >5 years. In an attempt to search for more effective therapies for this disease, we report here, for the first time, an effective treatment, the combination of gemcitabine and auristatin-phenethylamine (PE), against an orthotopic implantation of a human pancreatic adenocarcinoma cell line (HPAC) in severe combined immunodeficient (SCID) mice. Tumor implantation was performed by injecting 100 μl of the HPAC cell suspension (1 x 106 cells) directly into the pancreas of 5-week-old SCID mice. After implantation, tumor formation was checked twice a week. All palpable tumors were detected within 21 days (100{\%} take rate), and tumors were confirmed histologically to be pancreatic adenocarcinoma. For the subsequent efficacy trial, tumor-bearing SCID mice were randomized into four groups with five mice in each group. One served as a control, the second received gemcitabine alone (2.5 mg/kg/injection i.p.), the third received auristatin-PE alone (2.0 mg/kg/injection i.v.), and the fourth group received the combination of gemcitabine (i.p.) and auristatin-PE (1.5 mg/kg/injection i.v.). All animals were euthanized 7 days after the completion of their treatments, and the pancreases were resected. Histological examination revealed the tumors to be adenocarcinoma. The tumors were composed of diffuse sheets of cells interrupted by glandular spaces containing secretory material. Cytologically, the tumor cells were large, pleomorphic, and hyperchromatic. Many cells contained intracellular lumina containing mucin. Immunohistochemical studies showed strong p21(WAFI) (p21) expression but no immunoreactivity with p53 and Her-2/neu antibodies. The mean pancreatic weight in the gemcitabine/auristatin-PE combination group was significantly (P = 0.014) lower (0.84 ± 0.639 g) when compared with those of the control (2.91 ± 1.19 g) and gemcitabine alone (1.84 ± 0.796 g; P = 0.064) groups. In addition, the mean weight in the combination group approached statistical significance when compared with the auristatin-PE group alone (1.16 ± 0.635 g; P = 0.028). We conclude that the combination of gemcitabine and auristatin-PE is an effective treatment against HPAC tumors in this xenograft model and more effective than treatment with either gemcitabine or auristatin-PE alone and could be considered for future animal studies with pancreas cancer and/or for human clinical trials.",
author = "Mohammad, {Ramzi M.} and Ayad Al-Katib and George Pettit and Vaitkevicius, {Vainutis K.} and Urwashi Joshi and Volkan Adsay and Majumdar, {Adhip P N} and Sarkar, {Fazlul H.}",
year = "1998",
month = "4",
language = "English (US)",
volume = "4",
pages = "887--894",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice

T2 - Potential application for preclinical studies

AU - Mohammad, Ramzi M.

AU - Al-Katib, Ayad

AU - Pettit, George

AU - Vaitkevicius, Vainutis K.

AU - Joshi, Urwashi

AU - Adsay, Volkan

AU - Majumdar, Adhip P N

AU - Sarkar, Fazlul H.

PY - 1998/4

Y1 - 1998/4

N2 - Pancreatic adenocarcinoma is one of the most incurable and least understood of all human cancers. It is the fourth leading cause of cancer- related mortality in males (after lung, prostate, and colon) and in females (after lung, breast, and colon) in the United States with <2-3% of patients surviving >5 years. In an attempt to search for more effective therapies for this disease, we report here, for the first time, an effective treatment, the combination of gemcitabine and auristatin-phenethylamine (PE), against an orthotopic implantation of a human pancreatic adenocarcinoma cell line (HPAC) in severe combined immunodeficient (SCID) mice. Tumor implantation was performed by injecting 100 μl of the HPAC cell suspension (1 x 106 cells) directly into the pancreas of 5-week-old SCID mice. After implantation, tumor formation was checked twice a week. All palpable tumors were detected within 21 days (100% take rate), and tumors were confirmed histologically to be pancreatic adenocarcinoma. For the subsequent efficacy trial, tumor-bearing SCID mice were randomized into four groups with five mice in each group. One served as a control, the second received gemcitabine alone (2.5 mg/kg/injection i.p.), the third received auristatin-PE alone (2.0 mg/kg/injection i.v.), and the fourth group received the combination of gemcitabine (i.p.) and auristatin-PE (1.5 mg/kg/injection i.v.). All animals were euthanized 7 days after the completion of their treatments, and the pancreases were resected. Histological examination revealed the tumors to be adenocarcinoma. The tumors were composed of diffuse sheets of cells interrupted by glandular spaces containing secretory material. Cytologically, the tumor cells were large, pleomorphic, and hyperchromatic. Many cells contained intracellular lumina containing mucin. Immunohistochemical studies showed strong p21(WAFI) (p21) expression but no immunoreactivity with p53 and Her-2/neu antibodies. The mean pancreatic weight in the gemcitabine/auristatin-PE combination group was significantly (P = 0.014) lower (0.84 ± 0.639 g) when compared with those of the control (2.91 ± 1.19 g) and gemcitabine alone (1.84 ± 0.796 g; P = 0.064) groups. In addition, the mean weight in the combination group approached statistical significance when compared with the auristatin-PE group alone (1.16 ± 0.635 g; P = 0.028). We conclude that the combination of gemcitabine and auristatin-PE is an effective treatment against HPAC tumors in this xenograft model and more effective than treatment with either gemcitabine or auristatin-PE alone and could be considered for future animal studies with pancreas cancer and/or for human clinical trials.

AB - Pancreatic adenocarcinoma is one of the most incurable and least understood of all human cancers. It is the fourth leading cause of cancer- related mortality in males (after lung, prostate, and colon) and in females (after lung, breast, and colon) in the United States with <2-3% of patients surviving >5 years. In an attempt to search for more effective therapies for this disease, we report here, for the first time, an effective treatment, the combination of gemcitabine and auristatin-phenethylamine (PE), against an orthotopic implantation of a human pancreatic adenocarcinoma cell line (HPAC) in severe combined immunodeficient (SCID) mice. Tumor implantation was performed by injecting 100 μl of the HPAC cell suspension (1 x 106 cells) directly into the pancreas of 5-week-old SCID mice. After implantation, tumor formation was checked twice a week. All palpable tumors were detected within 21 days (100% take rate), and tumors were confirmed histologically to be pancreatic adenocarcinoma. For the subsequent efficacy trial, tumor-bearing SCID mice were randomized into four groups with five mice in each group. One served as a control, the second received gemcitabine alone (2.5 mg/kg/injection i.p.), the third received auristatin-PE alone (2.0 mg/kg/injection i.v.), and the fourth group received the combination of gemcitabine (i.p.) and auristatin-PE (1.5 mg/kg/injection i.v.). All animals were euthanized 7 days after the completion of their treatments, and the pancreases were resected. Histological examination revealed the tumors to be adenocarcinoma. The tumors were composed of diffuse sheets of cells interrupted by glandular spaces containing secretory material. Cytologically, the tumor cells were large, pleomorphic, and hyperchromatic. Many cells contained intracellular lumina containing mucin. Immunohistochemical studies showed strong p21(WAFI) (p21) expression but no immunoreactivity with p53 and Her-2/neu antibodies. The mean pancreatic weight in the gemcitabine/auristatin-PE combination group was significantly (P = 0.014) lower (0.84 ± 0.639 g) when compared with those of the control (2.91 ± 1.19 g) and gemcitabine alone (1.84 ± 0.796 g; P = 0.064) groups. In addition, the mean weight in the combination group approached statistical significance when compared with the auristatin-PE group alone (1.16 ± 0.635 g; P = 0.028). We conclude that the combination of gemcitabine and auristatin-PE is an effective treatment against HPAC tumors in this xenograft model and more effective than treatment with either gemcitabine or auristatin-PE alone and could be considered for future animal studies with pancreas cancer and/or for human clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0031943257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031943257&partnerID=8YFLogxK

M3 - Article

C2 - 9563882

AN - SCOPUS:0031943257

VL - 4

SP - 887

EP - 894

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -